Dr. Kleen is currently Executive VP Immune Monitoring at Epiontis. He received his Ph.D. in Biology with specialty in Immunology and Virology from the Bayerische Julius-Maximilians-University Würzburg, Bavaria, Germany. During his studies at Case Western Reserve University in Cleveland, Ohio, he investigated conditions of the human immune system affected by infectious diseases, and in particular the detailed monitoring of immune cell function in patients with human immune deficiency virus (HIV) infections. He further conducted research on the facilitation of umbilical cord blood stem cell transplantation for immune reconstitution of adult patients with life-threatening hematological disorders and malignancies after treatment with full myelo-ablative regimens. His expertise is in the areas of immunology, vaccine and biologic evaluation, immunogenicity and oncology. One focus is monitoring of Cell Mediated Immunity (CMI) and Bio-markers during immunotherapy, vaccine development and detection of adverse immune reactions during drug development. He spends significant time educating pharmaceutical entities and governmental agencies about validated, standardized, ISO and GLP compliant technologies, which can be deployed today during pre-clinical and clinical trials, for sample logistics and immune monitoring.
Immuno-Oncology Trial Monitoring Directly From Whole Blood or Tissue with qPCR-Assisted Cell Counting (qPACC)
Tuesday, 1 November 2016 at 17:00
Add to Calendar ▼2016-11-01 17:00:002016-11-01 18:00:00Europe/LondonImmuno-Oncology Trial Monitoring Directly From Whole Blood or Tissue with qPCR-Assisted Cell Counting (qPACC)Cancer Immunotherapy and Biofluid Biopsies 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Novel immunotherapy agents like anti-CTLA-4 and anti-PD1/PD-L1 have made immune monitoring in clinical trials a vital part based on the mechanism of action of these drugs. Monitoring both systemic changes in the blood and intra-tumoral changes of relevant leukocyte sub-populations aids the development of early surrogate markers of therapy success or warning signs of increased inflammatory processes or autoimmunity. Epigenetic based, quantitative real-time PCR assisted cell counting (qPACC) performed under ISO 17025 allows precise and robust quantification of immune cells in all human samples from only small amounts of blood or tissue. Samples can be simply frozen and easily shipped, leading to less costly logistics, far less sample requirements, and no need for viability and/or stability of cells as required for Flow cytometry and ELISPOT. This allows the unprecedented capability to monitor patients Immuno-oncology trials with regulatory T cells (Tregs), Th17 cells, Tfh cells, CD4+ and CD8+ cells, overall T cells (CD3+), B cells, NK cells (CD56 dim), neutrophil granulocytes and monocytes are the first examples of a next generation of Immuno-oncology biomarker tools that can be used in these settings.
Add to Calendar ▼2016-11-01 00:00:002016-11-02 00:00:00Europe/LondonCancer Immunotherapy and Biofluid Biopsies 2016Cancer Immunotherapy and Biofluid Biopsies 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-11-01 17:00:002016-11-01 18:00:00Europe/LondonImmuno-Oncology Trial Monitoring Directly From Whole Blood or Tissue with qPCR-Assisted Cell Counting (qPACC)Cancer Immunotherapy and Biofluid Biopsies 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
